{"id":81589,"date":"2025-07-21T21:12:13","date_gmt":"2025-07-21T21:12:13","guid":{"rendered":"https:\/\/www.europesays.com\/us\/81589\/"},"modified":"2025-07-21T21:12:13","modified_gmt":"2025-07-21T21:12:13","slug":"samsung-bioepis-releases-q3-biosimilar-market-trends-report","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/81589\/","title":{"rendered":"Samsung Bioepis Releases Q3 Biosimilar Market Trends Report"},"content":{"rendered":"<p class=\"pb-2\">Samsung Bioepis released its Third Quarter 2025 United States Biosimilar Market Report today, providing an insight into industry pricing trends, dynamics and the Most-Favored-Nation (MFN) policy, according to a <a rel=\"nofollow noopener\" target=\"_self\" href=\"https:\/\/www.samsungbioepis.com\/en\/newsroom\/newsroomView.do?idx=488&amp;currentPage=1\">news release<\/a>.<\/p>\n<p class=\"pb-2\">\u201cWhen we first launched this report in Q2 2023, the US market had seen the approval of 40 biosimilars, with 28 products commercially launched,\u201d Thomas Newcomer, vice president and head of U.S. commercial operations at Samsung Bioepis, said in the news release. \u201cAs of this tenth edition, the numbers have risen to 75 approvals and 53 launches, reflecting the market\u2019s accelerating pace and growing complexity.\u201d<\/p>\n<p class=\"pb-2\">In Q2, two biosimilars were approved by the FDA\u2014Starjemza (ustekinumab), referencing Stelara (ustekinumab) and Jobevne (bevacizumab), referencing Avastin (bevacizumab). Four biosimilars were also launched\u2014two in the denosumab market and two in the eculizumab market.<\/p>\n<p class=\"pb-2\">Read the slideshow above for the report highlights.<\/p>\n","protected":false},"excerpt":{"rendered":"Samsung Bioepis released its Third Quarter 2025 United States Biosimilar Market Report today, providing an insight into industry&hellip;\n","protected":false},"author":3,"featured_media":81590,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,24149,27654,24919,27653,27652,135,67,132,68],"class_list":{"0":"post-81589","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-c-suite","10":"tag-health-plans","11":"tag-health-systems","12":"tag-healthcare-executives","13":"tag-managed-care","14":"tag-markets","15":"tag-united-states","16":"tag-unitedstates","17":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114893287909536858","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/81589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=81589"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/81589\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/81590"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=81589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=81589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=81589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}